Peer-reviewed veterinary case report
Safety of vinblastine and toceranib combined for dog mast cell tumors
By Robat, C et al.·Published in Veterinary and comparative oncology·2012·School of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
- Species:
- dog
Plain-English summary
A group of dogs with mast cell tumors were treated with a combination of two cancer drugs, vinblastine and toceranib, to see if they could work better together. While the combination did show some effectiveness, with 71% of dogs responding positively, it also caused a significant drop in white blood cell counts, which can lead to infections. The researchers found that using a lower dose of vinblastine alongside toceranib was necessary to reduce side effects. More studies are needed to determine if this combination could be a better treatment option for dogs with these tumors.
People also search for: dog mast cell tumor treatment · vinblastine side effects in dogs · toceranib for dog cancer
Abstract
Combining drugs with known single-agent activity that lack overlapping dose-limiting toxicities (DLT) and exert antitumour activity through different mechanisms could improve clinical outcome. As toceranib and vinblastine meet these requisites, a phase I trial was performed in combination in dogs with mast cell tumours. The DLT for the simultaneous combination was neutropenia and the maximally tolerated dose was vinblastine (1.6 mg m(-2) every other week) concurrent with toceranib (3.25 mg kg(-1) PO, every other day). This represents greater than a 50% reduction in dose intensity for vinblastine (compared with single-agent use) and as such does not support this combination based on current drug combination paradigms. Although a strict adherence to dose paradigms speaks against the combination, evidence of significant activity (71% objective response) and enhanced myelosuppression suggest additive or synergistic activity. A prospective randomized evaluation comparing this combination with standard single-agent treatments would seem prudent to interrogate this potential.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22235914/